Lifting the mask on neurological manifestations of COVID-19
“As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic spreads, it is becoming increasingly evident that coronavirus disease 2019 (COVID-19) is not limited
Read moreNews
Gut metagenomics-derived genes as potential biomarkers of Parkinson’s disease.
“Identification of the gut microbiome compositions associated with disease has become a research focus worldwide. Emerging evidence has revealed the presence of gut microbiota
Read more
COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases.
“Although most autoimmune diseases are considered to be CD4 T cell- or antibody-mediated, many respond to CD20-depleting antibodies that have limited influence on CD4
Read moreNeurological immunotherapy in the era of COVID-19 – looking for consensus in the literature
“The coronavirus disease 2019 (COVID-19) pandemic is concerning for patients with neuroimmunological diseases who are receiving immunotherapy. Uncertainty remains about whether immunotherapies increase the
Read more
© 2020 Aini - Associazione Italiana di Neuroimmunologia